skip to content

Foundation Medicine

Blog

Foundation Forward

  • December 15, 2015

    Another Important Step Towards Revealing New Cancer Treatment Options: FoundationOne Identifies High Frequency of Clinically Relevant Genomic Alterations in Rare Cancer, Penile Squamous Cell Carcinoma

    New data published today in The Oncologist by Siraj M. Ali, M.D., Ph.D., our very own associate director, clinical development and medical affairs, along with our collaborators, revealed clinically relevant genomic alterations in penile squamous cell carcinoma (PSCC), a rare cancer for which the oncogenic drivers have …

    Continue Reading

  • December 11, 2015

    New Data Supports Genomic Profiling with FoundationOne Heme in Patients with Lymphomas and Multiple Myeloma

    Here at Foundation Medicine, we’re always excited when we can report important new data that could help improve clinical outcomes for patients. This week, at the American Society of Hematology (ASH) Annual Medical Meeting, we and our collaborators presented exciting new data supporting the use of FoundationOne Heme in …

    Continue Reading

  • November 16, 2015

    The Power of Information in Cancer: Foundation Medicine Identifies Previously Unreported BRAF-KD Events Across Tumor Types

    A new clinical case study published in a research letter in JAMA Oncology shows a beneficial clinical outcome for a patient with a rare tumor type as a result of comprehensive genomic profiling with FoundationOne. The patient, a woman in her 30’s, was diagnosed with an advanced acinic cell tumor of the right parotoid …

    Continue Reading

  • November 11, 2015

    Comprehensive Genomic Profiling Identifies Potential Targeted Therapy Options for Pediatric Cancer Patients with NTRK Fusions

    Pediatric cancer is devastating for patients and families, particularly when the diagnosis and appropriate course of therapy are difficult to determine. This was the case for a one-month-old with a recurrent sarcoma, eventually diagnosed as ETV6-NTRK3 negative congenital infantile fibrosarcoma (CIFS), whose disease …

    Continue Reading

  • October 5, 2015

    Foundation Medicine Responds to National Government Services’ DRAFT Local Coverage Determination in Lung Cancer

    Discordance Between Medicare Administrative Contractors’ Policies Threatens Uniform Access to Quality Care for Medicare Recipients with Lung Cancer National Government Services, Inc. (NGS), the Medicare Administrative Contractor, or MAC, that covers certain geographies of the United States, including Massachusetts, …

    Continue Reading

  • September 24, 2015

    Changing the Equation in Drug Development: The Important Role of Bio-Informatics in “Drug Rescue”

    Recent estimates cite the risk-adjusted cost of bringing a new drug to approval to be north of $2.5 billion. This is a staggering amount, particularly when less than 10 percent of newly innovated therapeutics survive the clinical development process. Indeed, drug development is fraught with high costs and low …

    Continue Reading

  • September 14, 2015

    Esophageal Cancers: The Oncologist Publishes New Data on Genomic Alterations that could be Targets for Current and Emerging Therapies

    A new study authored by Foundation Medicine scientists was published in the journal, The Oncologist, and provides clinical evidence that nearly all advanced esophageal cancers harbor genomic mutations that can be targeted with current or emerging drug therapies. Researchers at Foundation Medicine performed …

    Continue Reading

  • September 9, 2015

    Leading the Conversation on Genomics Knowledgebases at The Blueprint for Drug/Diagnostic Development Forum

    The Blueprint for Drug/Diagnostic Development: Facilitating Development and Use of Curated Genetic Databases forum was held this morning at The Mayflower in Washington D.C. Roman Yelensky, Ph.D., vice president, biomarker and companion diagnostic development at Foundation Medicine represented the company in the first …

    Continue Reading

  • August 19, 2015

    Next Generation Dx Summit: Foundation Medicine’s Matthew Hawryluk, Ph.D., Discusses Companion Diagnostics and NGS in Clinical Trials

    A key focus for all of us here at Foundation Medicine is to show how companion diagnostic development can deliver significant patient benefits, health care cost savings and value based payer coverage. On August 18 – 20, Matthew Hawryluk, Ph.D., vice president, corporate and business development at Foundation Medicine …

    Continue Reading

  • July 27, 2015

    Precision Medicine in Action: Comprehensive Genomic Profiling with FoundationOne® Heme Leads Patient to Clinical Trial

    A research brief published today in the online edition of the journal Cancer Discovery, provides clinical evidence for the utility of comprehensive genomic profiling in matching patients to targeted therapy clinical trials. A female patient with advanced soft tissue sarcoma widely metastatic to the lungs had a tumor …

    Continue Reading

Previous
  • 1
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
Next

Foundation Medicine

  • Genomic Testing
  • Insights & Trials
  • Partnerships
  • About Us
  • Blog
  • Careers
  • Contact Us
  • FAQ

Genomic Testing

  • Testing Overview
  • Financial Services & Support
  • Order a Test

Insights & Trials

  • Overview
  • FoundationSmartTrials™
  • FoundationInsights™

Partnerships

  • Overview
  • Institutional Partnerships
  • Biopharma Partnerships
  • LinkedIn
  • Twitter
  • YouTube

Legal & Privacy

© 2019 Foundation Medicine, Inc. v.1.6.5